// App-Quantinova.ai

4839 : Design of a Rofecoxib-Combretastatin hybrid drug that exerts highly potent antimicrotubule, anti-angiogenesis properties and Cox-2 inhibition both in cell culture and xenograft models

Researchers

Presenter

  • Surendra R. Punganuru

Principal Investigators

  • Hanumantha Rao Madala

  • Constantinos Mikelis

  • Kalkunte S. Srivenugopal

Medical Centers

  • Texas Tech University Health Sciences Center, Texas, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Colorectal Cancer

  • Fibroblastic sarcoma

  • Solid malignancies

  • Pancreatic and cerebellar agenesis

Biomarkers

  • Cadherin 1

  • Carbonic anhydrase IV

Drug/Treatment

  • NSC-348103

  • Rofecoxib

  • HT-1080

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved